Vaccination in the EU: benefits and barriers, European Parliament Committee on the Environment, Public Health and Food Safety
Professor Mike Catchpole, Chief Scientist of ECDC, presented to the Environment, Public Health and Food Safety Committee of the European Parliament during an exchange of views on vaccination.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Influenza vaccination of health care workers - can uptake be improved?
This online course was developed because seasonal influenza vaccination of health care workers (HCWs) is recommended in Europe but vaccination uptake remains low in most countries.
European Parliament resolution on the evaluation of the management of H1N1 influenza in 2009-2010 in the EUArchived
The European Parliament adopted a resolution on the evaluation of the pandemic in its sitting on the 8th March 2011.
Global Action Plan to increase supply of pandemic influenza vaccines (GAP-II)Archived
The objective of WHO’s Global Influenza Vaccine Action Plan (which began in 2006) is to increase the use and supply of influenza vaccines on a routine basis.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in EuropeArchived
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.